Get drug firms out of drug approval

In a commentary for APM's Marketplace, Dr. Stefan Kertesz questions the current process of approving new drugs, especially when researchers who set health care guidelines also have financial interests in pharmaceutical companies. He cites the timing  of the National Cholesterol Education Panel's announcement on recommended cholesterol levels and the drug Vytorin's release to illustrate the need for reform.